Avenue Therapeutics, Inc. (ATXI)
NASDAQ: ATXI · Real-Time Price · USD
1.860
-0.140 (-7.00%)
At close: Jan 8, 2025, 4:00 PM
1.929
+0.069 (3.73%)
After-hours: Jan 8, 2025, 4:00 PM EST
Avenue Therapeutics Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Avenue Therapeutics.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for ATXI.
Recommendation Trends
Rating | Aug '23 | Sep '23 | Oct '23 | Nov '23 | Dec '23 |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
Total | 1 | 1 | 1 | 1 | 0 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Maxim Group | Maxim Group | Strong Buy Initiates $56 | Strong Buy | Initiates | $56 | +2,924.19% | Dec 11, 2023 |
Aegis Capital | Aegis Capital | Strong Buy Initiates $2,400 | Strong Buy | Initiates | $2,400 | +128,932.26% | Apr 3, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $13,500 → $14,625 | Strong Buy | Maintains | $13,500 → $14,625 | +786,190.32% | May 12, 2020 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $12,375 | Strong Buy | Initiates | $12,375 | +665,222.58% | Jun 25, 2018 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-6.36
from -73.48
EPS Next Year
-2.00
from -6.36
Revenue Forecast
Revenue | 2024 | 2025 | 2026 |
---|---|---|---|
High | n/a | n/a | n/a |
Avg | n/a | n/a | n/a |
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 |
---|---|---|---|
High | -6.55 | -2.06 | -1.93 |
Avg | -6.36 | -2.00 | -1.88 |
Low | -6.12 | -1.92 | -1.80 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.